DK1200122T3 - Multikomponentvaccine til beskyttelse mod sygdom, som er forårsaget af Haemophilus influenzae og Moraxella catarrhalis - Google Patents

Multikomponentvaccine til beskyttelse mod sygdom, som er forårsaget af Haemophilus influenzae og Moraxella catarrhalis

Info

Publication number
DK1200122T3
DK1200122T3 DK00945494T DK00945494T DK1200122T3 DK 1200122 T3 DK1200122 T3 DK 1200122T3 DK 00945494 T DK00945494 T DK 00945494T DK 00945494 T DK00945494 T DK 00945494T DK 1200122 T3 DK1200122 T3 DK 1200122T3
Authority
DK
Denmark
Prior art keywords
moraxella catarrhalis
haemophilus influenzae
antigens
antigen
component
Prior art date
Application number
DK00945494T
Other languages
English (en)
Inventor
Sheena M Loosmore
Yan-Ping Yang
Michel H Klein
Ken Sasaki
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23389874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1200122(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of DK1200122T3 publication Critical patent/DK1200122T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00945494T 1999-07-15 2000-07-11 Multikomponentvaccine til beskyttelse mod sygdom, som er forårsaget af Haemophilus influenzae og Moraxella catarrhalis DK1200122T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/353,617 US6391313B1 (en) 1999-07-15 1999-07-15 Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
PCT/CA2000/000811 WO2001005424A2 (en) 1999-07-15 2000-07-11 Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis

Publications (1)

Publication Number Publication Date
DK1200122T3 true DK1200122T3 (da) 2007-06-04

Family

ID=23389874

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00945494T DK1200122T3 (da) 1999-07-15 2000-07-11 Multikomponentvaccine til beskyttelse mod sygdom, som er forårsaget af Haemophilus influenzae og Moraxella catarrhalis

Country Status (12)

Country Link
US (1) US6391313B1 (da)
EP (2) EP1880734A3 (da)
AT (1) ATE353223T1 (da)
AU (1) AU767096B2 (da)
CA (1) CA2378862C (da)
CY (1) CY1107620T1 (da)
DE (1) DE60033291T2 (da)
DK (1) DK1200122T3 (da)
ES (1) ES2280230T3 (da)
PT (1) PT1200122E (da)
SI (1) SI1200122T1 (da)
WO (1) WO2001005424A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
NZ517235A (en) * 1999-07-27 2004-01-30 Aventis Pasteur Recombinant high molecular weight major outer membrane protein of moraxella
SE0102410D0 (sv) 2001-07-04 2001-07-04 Arne Forsgren Novel surface exposed immunoglobulin D-binding protein from moraxella catarrhalis
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
CN105175549B (zh) * 2015-09-30 2019-08-16 康希诺生物股份公司 一种流感嗜血杆菌融合蛋白及其构建方法与应用
US11167022B2 (en) 2017-03-31 2021-11-09 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) * 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496538A (en) 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
FI914241A7 (fi) * 1989-03-09 1991-09-09 Praxis Biologics Inc Rokotteita ei-tyypitettävää Haemophilus influenzae-bakteereja vastaan
US5843463A (en) 1990-12-21 1998-12-01 Antexbiologics, Inc. Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae
US5603938A (en) 1992-03-16 1997-02-18 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
US5977336A (en) 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
KR100308234B1 (ko) * 1993-03-16 2001-11-30 세인트루이스유니버서티 비-정형헤모필루스의고분자량표면단백질들
US5712118A (en) * 1993-09-29 1998-01-27 Research Foundation Of State University Of New York Vaccine for branhamella catarrhalis
US5506139A (en) 1994-07-21 1996-04-09 Connaught Laboratories Limited Analog of haemophilus Hin47 with reduced protease activity
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
DE69533102T2 (de) 1994-07-21 2005-06-02 Aventis Pasteur Ltd., Toronto Analog von haemophilus hin47 mit verminderter protease aktivität
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
WO1999036086A1 (en) * 1998-01-13 1999-07-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipooligosaccharide-based vaccine for prevention of moraxella (branhamella) catarrhalis infections in mammals
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease

Also Published As

Publication number Publication date
EP1200122B1 (en) 2007-02-07
WO2001005424A2 (en) 2001-01-25
CA2378862A1 (en) 2001-01-25
SI1200122T1 (sl) 2007-08-31
CA2378862C (en) 2005-05-10
PT1200122E (pt) 2007-05-31
EP1880734A3 (en) 2008-06-25
WO2001005424A3 (en) 2001-08-02
US6391313B1 (en) 2002-05-21
ES2280230T3 (es) 2007-09-16
EP1880734A2 (en) 2008-01-23
EP1200122A2 (en) 2002-05-02
DE60033291T2 (de) 2007-07-05
AU5958600A (en) 2001-02-05
CY1107620T1 (el) 2013-03-13
DE60033291D1 (de) 2007-03-22
AU767096B2 (en) 2003-10-30
ATE353223T1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
DK0914153T3 (da) Multivalente DTP-poliovacciner
EP1398379A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis
DK1248647T3 (da) Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
DE69527202D1 (de) Proteinartige adjuvantien
DE69941567D1 (de) Antigene aus neisseria meningitidis
NO976060L (no) Vaksiner mot hepatitt C
EP1071451A4 (en) COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
WO2003065973A3 (en) Multivalent streptococcal vaccine compositions and methods for use
WO1998046725A3 (en) Attenuated, invasive vaccines against fish pathogens
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
CY1107620T1 (el) Πολυ-συστατικο εμβολιο για την προστασια εναντι της παθησης που προκαλειται απο haemophilus influenzae and moraxella catarrhalis
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
DK1140158T4 (da) Multikomponentvaccine omfattende mindst to antigener fra Haemophilus influenzae
WO2002009749A3 (en) Respiratory syncytial virus vaccine
WO2000051633A3 (en) MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE)
WO2004041182A3 (en) M. haemolytica outer membrane protein plpe as a vaccine or vaccine component against shipping fever
EP0591384A4 (en) ATTENUATED RE-MUTURED VIRUS VACCINE AGAINST MAREKS DISEASE SEROTYPE-1.
ATE401341T1 (de) Vakzine enthaltend omp85 proteine von neisseria gonorrhoeae und neisseria meningitidis